<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00520000</url>
  </required_header>
  <id_info>
    <org_study_id>LCCC0412</org_study_id>
    <secondary_id>CDR0000561620</secondary_id>
    <nct_id>NCT00520000</nct_id>
    <nct_alias>NCT00254098</nct_alias>
  </id_info>
  <brief_title>Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase I Trial of Carboplatin and Abraxane in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNC Lineberger Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>UNC Lineberger Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy such as paclitaxel albumin-stabilized nanoparticle
      formulation and carboplatin work in different ways to stop the growth of tumor cells, either
      by killing the cells or by stopping them from dividing. Giving paclitaxel albumin-stabilized
      nanoparticle formulation together with carboplatin may kill more tumor cells.

      PURPOSE: This phase I trial is studying the side effects, the best way to give, and the best
      dose of paclitaxel albumin-stabilized nanoparticle formulation when given together with
      carboplatin in treating patients with advanced or metastatic solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the maximum tolerated dose (MTD) of paclitaxel albumin-stabilized nanoparticle
           formulation given once weekly for 3 weeks when administered with carboplatin given once
           every 4 weeks.

        -  Determine the MTD of paclitaxel albumin-stabilized nanoparticle formulation given once
           every 3 weeks when administered with carboplatin given once every 3 weeks.

        -  Determine the MTD of paclitaxel albumin-stabilized nanoparticle formulation given in
           weeks 1 and 2 when administered with carboplatin given once every 3 weeks.

        -  Evaluate sequence-dependent effects on toxicity and pharmacokinetics in the combination
           of paclitaxel albumin-stabilized nanoparticle formulation and carboplatin.

      Secondary

        -  Explore the antitumor activity of paclitaxel albumin-stabilized nanoparticle formulation
           given once weekly or once every 3 weeks.

      OUTLINE: Patients are assigned to 1 of 3 treatment arms.

        -  Arm I: Patients receive carboplatin IV over 30 minutes on day 1 and paclitaxel
           albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15.
           Treatment repeats every 28 days for up to 6 courses in the absence of disease
           progression or unacceptable toxicity.

        -  Arm II: Patients receive carboplatin IV over 30 minutes on day 1 and paclitaxel
           albumin-stabilized nanoparticle formulation IV over 30 minutes on day 1. Treatment
           repeats every 21 days for up to 6 courses in the absence of disease progression or
           unacceptable toxicity.

        -  Arm III: Patients receive carboplatin IV over 30 minutes on day 1 and paclitaxel
           albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1 and 8.
           Treatment repeats every 21 days for up to 6 courses in the absence of disease
           progression or unacceptable toxicity.

      Patients in arms I and II undergo blood sample collection periodically for pharmacokinetic
      studies.

      After completion of study treatment, patients are followed at 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of Abraxane</measure>
    <time_frame>28 days</time_frame>
    <description>To determine the maximum tolerated dose (MTD) of Abraxane weekly days 1, 8, 15 with a carboplatin dose of AUC=6 given on day 1 of a 28 day cycle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of Abraxane given with Carboplatin</measure>
    <time_frame>21 days</time_frame>
    <description>To determine the MTD of Abraxane given every 3 weeks with carboplatin given on day 1 of a 21 day cycle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sequence-dependent toxicity</measure>
    <time_frame>28 days</time_frame>
    <description>To determine if there is any correlation to toxicity based on the order Abraxane and carboplatin are adminstered</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Weekly Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carboplatin day 1, abraxane days 1, 8, 15 every 28 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Every 3 week Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin day 1, abraxane day 1, every 21 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin day 1, abraxane day 1, 8 every 21 day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>standard dose of area under the curve (AUC) AUC of 6 in all arms</description>
    <arm_group_label>Weekly Arm</arm_group_label>
    <arm_group_label>Every 3 week Arm</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abraxane</intervention_name>
    <description>75mg/m2 - 150 mg/m2 given on days 1, 8, 15 of every 28 day cycle</description>
    <arm_group_label>Weekly Arm</arm_group_label>
    <other_name>Paclitaxil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abraxane</intervention_name>
    <description>180mg/m2 - 340mg/m2, repeated every 21 days</description>
    <arm_group_label>Every 3 week Arm</arm_group_label>
    <other_name>Paclitaxil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abraxane</intervention_name>
    <description>100mg/m2 - 175/mg/m2 given on days 1, 8 of every 21 day cycle</description>
    <arm_group_label>Arm C</arm_group_label>
    <other_name>Paclitaxil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

        Inclusion criteria:

          -  Histologically or cytologically confirmed solid tumor

               -  Advanced or metastatic disease

          -  Measurable or evaluable disease

          -  Must meet 1 of the following criteria:

               -  Failed a standard therapy

               -  Not a candidate for standard therapy

               -  Have a disease for which there is no defined standard therapy

        Exclusion criteria:

          -  Symptomatic brain metastases

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  ECOG performance status 0-2

          -  Life expectancy ≥ 8 weeks

          -  Absolute neutrophil count &gt; 1,500/mm^3

          -  Platelet count &gt; 100,000/mm^3

          -  Hemoglobin &gt; 8.0 g/dL

          -  Total bilirubin normal

          -  Serum creatinine normal OR creatinine clearance ≥ 60 mL/min

          -  AST and ALT ≤ 2.5 x upper limit of normal

          -  Negative pregnancy test

        Exclusion criteria:

          -  Pregnant or lactating

          -  Prior anaphylactic reaction or severe allergic reaction to paclitaxel and/or docetaxel

          -  Active infection that requires treatment with antibiotics for &gt; 4 weeks

          -  Uncontrolled congestive heart failure

          -  Symptomatic coronary artery disease or heart block

          -  Myocardial infarction within the past 3 months

          -  Peripheral neuropathy ≥ grade 2 from any cause

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy, radiotherapy, or any other therapy for malignancy within the
             past 3 weeks

          -  No concurrent filgrastim, pegfilgrastim, or sargramostim during the first course of
             therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas E. Stinchcombe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC Lineberger Comprehensive Cancer Center</affiliation>
  </overall_official>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2007</study_first_submitted>
  <study_first_submitted_qc>August 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2007</study_first_posted>
  <last_update_submitted>March 5, 2012</last_update_submitted>
  <last_update_submitted_qc>March 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

